Ahluwalia, Tarunveer S. http://orcid.org/0000-0002-7464-3354
Schulz, Christina-Alexandra
Waage, Johannes
Skaaby, Tea
Sandholm, Niina
van Zuydam, Natalie
Charmet, Romain
Bork-Jensen, Jette
Almgren, Peter
Thuesen, Betina H.
Bedin, Mathilda
Brandslund, Ivan
Christensen, Cramer K.
Linneberg, Allan
Ahlqvist, Emma
Groop, Per-Henrik
Hadjadj, Samy
Tregouet, David-Alexandre
Jørgensen, Marit E.
Grarup, Niels
Pedersen, Oluf
Simons, Matias
Groop, Leif
Orho-Melander, Marju
McCarthy, Mark I.
Melander, Olle
Rossing, Peter
Kilpeläinen, Tuomas O.
Hansen, Torben
Funding for this research was provided by:
Lundbeckfonden (Travel grant Reference #2013-14471)
Article History
Received: 7 August 2018
Accepted: 22 October 2018
First Online: 13 December 2018
Duality of interest
: P-HG has received investigator-initiated research grants from Lilly and Roche, is an advisory board member for AbbVie, AstraZeneca, Boehringer Ingelheim, Cebix, Lilly, Janssen, Medscape, Merck Sharp & Dohme, Novartis, Novo Nordisk and Sanofi and has received lecture fees from AstraZeneca, Boehringer Ingelheim, Lilly, Elo Water, Genzyme, Merck Sharp & Dohme, Medscape, Novo Nordisk and Sanofi. PR received consultancy and/or speaking fees (to institution) from AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, MSD, Novo Nordisk and Sanofi Aventis and has received research grants from AstraZeneca and Novo Nordisk. PR also has shares in Novo Nordisk. All other authors declare that there is no duality of interest associated with this manuscript.